Who is sponsoring pathfinder™5?

pathfinder™5 is sponsored by Novo Nordisk A/S.

What condition does pathfinder™5 study?

pathfinder™5 studies Congenital Bleeding Disorder, Haemophilia A.

What drugs are being tested in pathfinder™5?

Interventions: turoctocog alfa pegol.

What is the status of pathfinder™5?

pathfinder™5 is currently COMPLETED.

Last reviewed 2020-11-23 · How we verify

A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (pathfinder™5)

NCT01731600 PHASE3 COMPLETED Results posted

This trial is conducted globally. The aim of the trial is to investigate safety, efficacy and pharmacokinetics (the exposure of the trial drug in the body) of NNC 0129-0000-1003 (N8-GP) in children with severe haemophilia A who have undergone treatment with previous factor VIII (FVIII) products.

Details

Lead sponsor	Novo Nordisk A/S
Phase	PHASE3
Status	COMPLETED
Enrolment	68
Start date	Wed Feb 20 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Sep 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Congenital Bleeding Disorder
Haemophilia A

Interventions

turoctocog alfa pegol

Countries

France, Italy, Japan, Greece, Malaysia, Ukraine, United Kingdom, Israel, Canada, Lithuania, Puerto Rico, Switzerland, Portugal, United States, Turkey (Türkiye), Brazil